Dementia – Pipeline Review, H1 2019

Research By Markets adds Market Research Report - Dementia – Pipeline Review, H1 2019

For detailed information: https://www.researchbymarkets.com/report/dementia-pipeline-review-h1-2019-86784.html

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment

Dementia – Pipeline Review, H1 2019

Summary

Dementia – Pipeline Review, H1 2019, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person’s daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Dementia – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 17, 20, 48, 17 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Acadia Pharmaceuticals Inc
Acorda Therapeutics Inc
Actinogen Medical Ltd
Adamed Sp z oo
AgeneBio Inc
Alector Inc
Allergan Plc
Anavex Life Sciences Corp
Asceneuron SA
Axon Neuroscience SE
Axovant Sciences Ltd
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim GmbH
Bolder Biotechnology Inc
Cortice Biosciences Inc
CSPC NBP Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Eisai Co Ltd
Eli Lilly and Co
Ensol Biosciences Inc
EVER Neuro Pharma GmbH
GW Pharmaceuticals Plc
H. Lundbeck AS
HSRx Group
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
Ionis Pharmaceuticals Inc
IRLAB Therapeutics AB
Ironwood Pharmaceuticals Inc
Johnson & Johnson
M3 Biotechnology Inc
MediPost Co Ltd
MGC Pharmaceuticals Ltd
Neuraltus Pharmaceuticals Inc
Neurimmune Holding AG
NeuroScientific Biopharmaceuticals Ltd
Oryzon Genomics SA
Otsuka Holdings Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Pharmasum Therapeutics AS
Prana Biotechnology Ltd
ProMIS Neurosciences Inc
Prothena Corp Plc
Resverlogix Corp
Rodin Therapeutics Inc
Sage Therapeutics Inc
Sinil Pharmaceutical Co Ltd
Stemedica Cell Technologies Inc
Suven Life Sciences Ltd
T3D Therapeutics Inc
Theranexus SAS
UniQure NV
Vicore Pharma AB
Voyager Therapeutics Inc
WAVE Life Sciences Ltd
WhanIn Pharmaceutical Co Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/86784

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via ritesh@researchbymarkets.com. *Market Research News is a part of Research By Markets.